Document Detail


Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
MedLine Citation:
PMID:  8467623     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This multicenter, randomized, double-blind study was designed to compare the safety and efficacy of cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections. Patients were aged > or = 12 years with acute (< or = 7 days duration), single-site skin or skin-structure infections. The 7- to 10-day treatment regimens were cefpodoxime proxetil (400 mg cefpodoxime) orally with food twice a day with cefaclor-matched placebo (orally, fasting, three times a day); or cefaclor (Ceclor; 500 mg anhydrous equivalent) orally, fasting, three times a day, with cefpodoxime-matched placebo (orally with food twice a day). Clinical progress and cultures were evaluated upon admission to the study; on study days 7-10 and 15-18; and 2-3 weeks after treatment. Cefpodoxime had lower minimum inhibitory concentrations against the majority of Staphylococcus species than did cefaclor. Both treatments were highly effective (99% pathogen eradication and 86% cure rate). These high eradication rates were not unexpected in this study of minor infections in which patients with resistant pathogens were excluded. Cefaclor had a higher failure rate [2 (4%) of 57], than did cefpodoxime [2 (1%) of 139; p not significant]. Most patients in both groups completed treatment as planned: 185 (74%) of 249 cefpodoxime-treated patients and 91 (75%) of 122 cefaclor-treated patients. Both treatments were well tolerated and considered safe and effective in the treatment of skin and skin structure infections. However, the twice-a-day dosing regimen for cefpodoxime proxetil compared with the three-times-a-day regimen for cefaclor may result in better patient compliance.
Authors:
D L Stevens; F Pien; M Drehobl
Related Documents :
23426153 - An outcome study for ulnar neuropathy at the elbow: a multicenter study by the sun stud...
24499533 - Accuracy and precision of calibrated arterial pulse contour analysis in patients with s...
22418633 - Evaluation of postprescription review and feedback as a method of promoting rational an...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diagnostic microbiology and infectious disease     Volume:  16     ISSN:  0732-8893     ISO Abbreviation:  Diagn. Microbiol. Infect. Dis.     Publication Date:  1993 Feb 
Date Detail:
Created Date:  1993-05-12     Completed Date:  1993-05-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8305899     Medline TA:  Diagn Microbiol Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  123-9     Citation Subset:  IM    
Affiliation:
VA Medical Center, Boise, Idaho 83702.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Bacterial Infections / drug therapy
Cefaclor / administration & dosage,  adverse effects,  therapeutic use*
Ceftizoxime / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Connective Tissue Diseases / drug therapy*
Double-Blind Method
Drug Administration Schedule
Drug Resistance, Microbial
Female
Humans
Male
Middle Aged
Prodrugs / administration & dosage,  adverse effects,  therapeutic use*
Safety
Skin Diseases, Bacterial / drug therapy*
Staphylococcal Infections / drug therapy
Chemical
Reg. No./Substance:
0/Prodrugs; 53994-73-3/Cefaclor; 68401-81-0/Ceftizoxime; 87239-81-4/cefpodoxime proxetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Species identification and determination of high-level aminoglycoside resistance among enterococci. ...
Next Document:  In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis.